This early phase randomized, single-masked, 6-week investigation of SMT, LT and WLC enrolled 66 female Stage 0-III breast cancer survivors age 32–72 who had received surgery plus radiation and/or chemotherapy/chemoprevention with CRF (Brief Fatigue Inventory > 25). The primary outcome was the Multidimensional Fatigue Inventory (MFI), with the NIH PROMIS Fatigue scale secondary.